Novartis Files For Approval Of Parkinson’s Combination Drug ELC200 In Japan
This article was originally published in PharmAsia News
Executive Summary
Novartis filed for approval of ELC200, a combination drug containing levodopa, carbidopa hydrate, and entacapone, for the treatment of the wearing-off phenomenon associated with Parkinson’s disease in Japan on June 27